<DOC>
	<DOCNO>NCT02578316</DOCNO>
	<brief_summary>The purpose study determine metabolism elimination 14C-lenvatinib participant advance solid tumor lymphomas , unsuitable , fail , exist therapy .</brief_summary>
	<brief_title>A Study Determine Metabolism Elimination 14C-E7080 Patients With Advanced Solid Tumors Lymphomas , Who Are Unsuitable For , Have Failed , Existing Therapies .</brief_title>
	<detailed_description>The study comprise two phase , Study Phase Extension Phase . Participants receive 14C-lenvatinib Day 1 Study Phase . Thereafter participant give daily oral dos 24 mg lenvatinib 28 day cycle . During Study Phase , participant receive initial single dose 14C-lenvatinib oral patient dose solution contain 24 mg lenvatinib anhydrous free base radioactivity 100 mCi ( 3.7 MBq ) Day 1 , follow collection blood , urine feces sample pharmacokinetic analysis Day 1 Day 8 , discharge visit Day 8 . Participants enter Extension Phase study continue receive daily oral administration non-radiolabeled lenvatinib dose 24 mg. Each 28-day dosing period consider one treatment cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Participants histologically and/or cytologically confirm solid tumor lymphoma resistant/ refractory approve therapy appropriate therapy available . Participants measurable tumor accord RECIST desirable essential inclusion . 2 . All previous treatment ( include surgery radiotherapy ) must complete least four week prior study entry acute toxicity must resolve 3 . Aged great equal 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 5 . Could take oral study medication 6 . Gave write informed consent participate study 7 . Willing comply study protocol duration study . EXCLUSION CRITERIA 1 . Participants brain subdural metastasis , unless complete local therapy discontinue use corticosteroid indication least 4 week start treatment study . Any sign and/or symptom brain metastasis stable least 4 week . 2 . Participants meningeal carcinomatosis 3 . Any following value laboratory parameter : 1. hemoglobin less 9 g/dL ( 5.6 mmol/L ) ; 2. neutrophil less 1.5 x 10^9/L ; 3. platelet less 100 x 10^9/L ; 4 . Prothrombin time ( PT ) [ International Normalized Ratio ( INR ) ] Patial thromboplastin time ( PTT ) &gt; 1.5 x upper limit normal ( ULN ) 5. serum bilirubin great 1.5 x ULN 6. liver parameter great 3 x ULN 7. creatinine clearance le 60 mL/min per Cockcroft Gault formula 4 . Uncontrolled infection 5 . Significant cardiovascular impairment ( history congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable ischemic heart disease include myocardial infarction within six month study start , serious cardiac arrhythmia ) 6 . Participants mark baseline prolongation QT/QT interval correct heart rate ( QTc ) interval ( QTc interval great equal 500 msec ) use Fridericia method 7 . Any treatment investigational drug within last 30 day 8 . Women pregnant breastfeeding ; woman childbearing potential positive pregnancy test screening pregnancy test . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator ( include two form contraception , one must barrier method ) . Perimenopausal woman amenorrheic least 12 month consider nonchildbearing potential . Fertile male female partner childbearing potential willing use contraception , whose female partner use adequate contraceptive protection , exclude . 9 . Proteinuria great 1+ bedside test 10 . History gastrointestinal malabsorption 11 . Surgery within four week start study treatment 12 . Bleeding thrombotic disorder use anticoagulant , warfarin , therapeutic INR . Aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) , low molecular weight heparin ( LMWH ) permissible use caution . 13 . Poorly control hypertension ( defined change hypertensive therapy within three month study start ) participant diagnose hypertension ( define repeat blood pressure measurement 160/90 mmHg high ) screen 14 . Previous lenvatinib therapy 15 . History alcoholism , drug addiction , psychiatric psychological condition , social situation , opinion investigator , would impair study compliance 16 . History allergic reaction attribute compound similar chemical biological composition lenvatinib 17 . Other significant disease disorder , Investigator 's opinion , would exclude participant study 18 . Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Lymphomas</keyword>
</DOC>